Dermira Inc (NASDAQ:DERM) insider Eugene A. Bauer sold 3,000 shares of the business’s stock in a transaction that occurred on Monday, December 18th. The stock was sold at an average price of $27.34, for a total transaction of $82,020.00. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.
Dermira Inc (NASDAQ:DERM) traded down $0.88 during trading hours on Friday, reaching $28.01. 352,050 shares of the company’s stock traded hands, compared to its average volume of 547,903. Dermira Inc has a 12 month low of $21.35 and a 12 month high of $38.75. The company has a current ratio of 4.68, a quick ratio of 4.68 and a debt-to-equity ratio of 1.40.
Several research firms recently commented on DERM. BidaskClub upgraded shares of Dermira from a “hold” rating to a “buy” rating in a research note on Wednesday. Guggenheim reiterated a “buy” rating and set a $30.00 price objective on shares of Dermira in a research note on Thursday, December 14th. Mizuho reduced their price objective on shares of Dermira from $43.00 to $39.00 and set a “buy” rating for the company in a research note on Tuesday, December 12th. Cantor Fitzgerald set a $45.00 target price on shares of Dermira and gave the stock a “buy” rating in a research report on Wednesday, November 29th. Finally, Zacks Investment Research downgraded shares of Dermira from a “hold” rating to a “sell” rating in a research report on Thursday, November 9th. Four equities research analysts have rated the stock with a sell rating and seven have assigned a buy rating to the stock. Dermira currently has an average rating of “Hold” and an average price target of $41.00.
COPYRIGHT VIOLATION WARNING: This story was originally reported by Community Financial News and is owned by of Community Financial News. If you are viewing this story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this story can be viewed at https://www.com-unik.info/2017/12/23/insider-selling-dermira-inc-derm-insider-sells-82020-00-in-stock.html.
Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.
What are top analysts saying about Dermira? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Dermira and related companies.